UCLA-led research shows that prior treatments influence immunotherapy response in advanced melanoma

UCLA researchers awarded $3.2M NIH grant to improve detection and treatment of glioblastoma

Researchers from the UCLA Jonsson Comprehensive Cancer Center have been awarded a $3.2 million grant from NIH to develop advanced imaging and surgical strategies aimed at improving outcomes for patients with glioblastoma, a fast-growing and aggressive brain tumor.

June 18, 2026

Vol.52 No.24

AI in action: MANAscore tool moves closer to clinic

One of the greatest challenges in cancer immunotherapy is finding the rare immune cells, called tumor-reactive T cells, whose job it is to recognize and eliminate tumor cells.

June 05, 2026

Vol.52 No.22

In Brief

UCLA researchers awarded $3.2M NIH grant to develop AI tool for more personalized liver cancer treatment

Jason Chiang and Kyung Sung of the Department of Radiological Sciences at the David Geffen School of Medicine at UCLA and the UCLA Health Jonsson Comprehensive Cancer Center have received a $3.2 million, five-year grant from NCI to develop an artificial intelligence-enhanced imaging platform designed to improve yttrium-90 (Y90) radioembolization planning for patients with liver cancer.

June 05, 2026

Vol.52 No.22

Clinical Roundup

Cytokine-armored CAR T-cell therapy helps eliminate aggressive brain tumors in UCLA preclinical study

Scientists at the UCLA Health Jonsson Comprehensive Cancer Center have developed a cytokine-armored CAR T-cell therapy that helps the immune system better attack aggressive brain tumors in mice while reducing dangerous side effects that have long limited immune-based treatments for glioblastoma, one of the deadliest and most treatment-resistant brain cancers.

May 29, 2026

Vol.52 No.21

Clinical Roundup

Intismeran cancer vaccine + Keytruda sustains 49% melanoma reduction after five years

A combination of a cancer vaccine and a drug, both of which harness the immune system to attack cancer cells, has proven successful in cutting the risk of skin cancer recurrence and death by 49%, according to a study led by researchers at NYU Langone Health and its Perlmutter Cancer Center.

May 22, 2026

Vol.52 No.20

Houston Methodist researchers identify B cells as driver of immunotherapy resistance in liver cancer

Despite major advances in immunotherapy, most patients with hepatocellular carcinoma fail to respond to current immune checkpoint inhibitors.

May 15, 2026

Vol.52 No.19

By Dan G. Duda

UCLA-led research shows that prior treatments influence immunotherapy response in advanced melanoma

YOU MAY BE INTERESTED IN

UCLA researchers awarded $3.2M NIH grant to improve detection and treatment of glioblastoma

AI in action: MANAscore tool moves closer to clinic

UCLA researchers awarded $3.2M NIH grant to develop AI tool for more personalized liver cancer treatment

Cytokine-armored CAR T-cell therapy helps eliminate aggressive brain tumors in UCLA preclinical study

Intismeran cancer vaccine + Keytruda sustains 49% melanoma reduction after five years

Houston Methodist researchers identify B cells as driver of immunotherapy resistance in liver cancer

Renew today!

Subscriber content

Never miss an issue!

Login